Annual Report

1 July 2024 to 30 June 2025

Australia and New Zealand Transplant and Cellular Therapies Ltd

Based on reports to members at the Annual General Meeting, 6 August 2025, Twin Towns Conference Centre

ANZTCT acknowledges the Traditional Custodians of the lands on which we work, and pays respect to Elders past and present. We recognise Māori as Tangata Whenua of Aotearoa New Zealand and embrace Te Tiriti o Waitangi.

About ANZTCT

Australia and New Zealand Transplant and Cellular Therapies Ltd (ANZTCT), formerly the Bone Marrow Transplant Society of Australia and New Zealand, is the multidisciplinary professional body for haematopoietic stem cell transplantation and cellular therapies in Australia and New Zealand. ANZTCT is a company limited by guarantee and a registered charity, and operates the ANZTCT Registry, the national clinical quality registry for transplant and cellular therapy.

Our purpose is to improve outcomes for Australians and New Zealanders of all ages undergoing transplantation of blood or marrow stem cells and other cellular therapies, through innovation and improvement in clinical care, and to foster clinical and laboratory research in the field.

49,000	4	284	+37%
Transplants held in the Registry	MRFF grant applications supported	Members at 1 August 2025	Membership growth

President's report

2024-25 was the year ANZTCT became an independent national organisation. The ANZTCT Registry transitioned from St Vincent's Hospital Sydney to ANZTCT ownership, establishing ANZTCT as an independent national clinical quality registry, and we set up our own headquarters in Surry Hills, Sydney.

Alongside this transition, the Society grew in membership, reach and influence. We held our third Annual Scientific Meeting with record attendance and engagement, expanded our patient education work, strengthened our governance, and deepened our national and international partnerships.

Highlights of the year

- Transition of the ANZTCT Registry from SVHS to ANZTCT ownership, and establishment of ANZTCT as an independent national clinical quality registry.
- Establishment of ANZTCT headquarters in Surry Hills.
- Record attendance and engagement at the 3rd Annual Scientific Meeting.
- Expanded patient education, including Clinical Practice Statements, the Wiley MSA and Arrow Books.
- Support for MSAC submissions for CAR-T indications.
- Support and partnership in four MRFF grant applications.
- Successful financial audit, a skills-based Board, two new committees (Education; Scientists) and two new SIGs (Allied Health; Joint Donor SIG).
- Ongoing partnership in the Blood Cancer Taskforce and state-level advisory roles.
- Active collaborations with EBMT, ASTCT, WBMT, CTTC, BSBMTCT, CIBMTR and FACT.
- Stronger advocacy on access, equity and patient experience.

Governance

ANZTCT is governed by a skills-based Board of Directors. Governance, company secretarial and finance services are provided by The Breakthrough Office (TBO), member services and the ASM by Slattery Australia, and website services by Third Wunder. The financial statements for the year were audited by SDJA.

- From January 2025, The Breakthrough Office has provided ANZTCT's company secretarial and accounting services.
- A suite of organisational policies was approved by the Board in the first half of 2025, giving a policy framework for staff, Directors and committee members.
- ACNC reporting and compliance were maintained, with the 2024-25 Annual Information Statement on track for lodgement before the deadline.

Board of Directors at 30 June 2025

Director	Role / background	Appointed
Prof Nada Hamad	President and Board Chair	10 July 2020
Dr Jason Butler	Treasurer	10 July 2020
A/Prof Ashish Bajel	Director	10 July 2020
Dr Duncan Purtill	Director	10 July 2020
Dr Richard Doocey	Director (New Zealand)	10 July 2020
Dr Theresa Cole	Director	5 August 2022
Dr David Yeung	Director	7 October 2022
Megan Hogg	Director	11 November 2022
Dr Annette Trickett	Director	4 August 2023
Ms Leonie Wilcox	Director; Registry Executive Director	10 November 2023

Membership

Membership grew from 207 at 1 September 2024 to 284 at 1 August 2025, an increase of 37%. Our five most represented institutions were Royal Brisbane and Women's Hospital (QLD), Westmead Hospital (NSW), The Alfred (VIC), Peter MacCallum Cancer Centre (VIC) and St Vincent's Hospital (NSW).

ANZTCT Registry

During 2024-25 the Registry moved under ANZTCT ownership and operations. As reported at the 2024 AGM, the Registry held records of approximately 49,000 transplants, including around 2,300 performed in 2023, and around 650 standard-of-care CAR-T treatments, and was engaged in CAR-T centre accreditation and alignment with CIBMTR. Through the year it continued national data collection for allogeneic and autologous transplantation and CAR-T, reporting to participating centres, and its role in CAR-T surveillance. A full Registry activity report was presented to members at the 2025 AGM.

Committees and Special Interest Groups

Scientific Meeting Committee

The 2025 ASM ran over five days, including three core days, FACT training, and Nursing, Pharmacy and Data Manager programs, a CLL spotlight, a Lymphoma Symposium and a Myeloma Spotlight. It featured 10 international keynotes, 16 oral abstracts, three Lunch 'n' Learns, debates and patient-led sessions, with faculty from CIBMTR, EBMT, Fred Hutch, Mount Sinai, Peter Mac and QIMR. An IMJ supplement was planned to publish the abstracts. Engagement with ACSQHC, MSAC and the TGA was strengthened, and partnerships with Arrow and Stem Cell Donors Australia continued.

Nurses Committee

Nursing membership grew 68%, from 38 in 2024 to 64 in 2025. The Committee delivered webinars on ASM highlights (October 2024), FACT-JACIE standards for nursing practice (March 2025) and outpatient AML induction in partnership with HSANZ (June 2025), and a pre-conference workshop in August 2025.

Pharmacy SIG

Working through education, competency, communication and (new in 2025) research craft groups, the SIG delivered a dedicated Pharmacist Workshop at the 2025 ASM, advanced a competency framework and standards, and developed governance to support its growth.

Total Body Irradiation SIG

Representing 51 medical physicists, 12 radiation oncologists and 11 radiation therapists across the 19 ANZ clinics delivering TBI, the SIG completed a national patterns-of-practice survey, worked with the Registry to capture radiation parameters such as lung and kidney doses, and agreed an MOU between ANZTCT and ACPSEM, with an MOU with ASMIRT under negotiation.

Quality Managers SIG

Membership grew from 8 to 15. The SIG worked with Stem Cell Donors Australia to add an eligibility statement to donor paperwork, delivered Quality Management training with FACT at the ASM, developed a standardised Quality Manager role description and audit templates for FACT-JACIE mandatory audits, and began work on a Quality Manager Certification Program.

Data Managers SIG

With 15 members, the SIG was represented at the CIBMTR/ASTCT Tandem Meetings and delivered a full-day combined ANZTCT-CIBMTR Data Manager Workshop at the 2025 ASM, with industry support.

Financial summary

ANZTCT's 2024-25 financial statements were audited by SDJA, which issued an unmodified opinion, and the going concern basis was considered appropriate. Income in 2024-25 funded the transition of the Registry to ANZTCT and the establishment of our headquarters.

The full audited financial statements are available on request.

Priorities for 2025-26

- An outward-facing Strategic Plan.
- Registry compliance with the national Clinical Quality Registry framework.
- Expansion of education and credentialling pathways.
- FACT readiness across Australia and New Zealand.
- National and international partnerships and collaborations.

We thank our Board, committee and SIG chairs, Registry staff, members, patient community, sponsors and international partners for their contribution this year.

Prof Nada Hamad

President and Board Chair